AC   CVCL_9916
DR   Cosmic; 1084281
DR   Cosmic; 1162844
DR   Cosmic; 2036689
DR   Cosmic; 2328761
DR   Wikidata; Q54995073
RX   PubMed=9669284;
RX   PubMed=11349830;
RX   PubMed=16646677;
RX   PubMed=16778181;
RX   PubMed=17725429;
RX   PubMed=19087340;
RX   PubMed=26354775;
RX   PubMed=29066502;
RX   PubMed=31443247;
CC   Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502).
CC   Doubling time: 103 +- 6.7 hours (PubMed=9669284).
CC   Sequence variation: Heteroplasmic for MT-CYB p.Glu271Lys (m.15557G>A); in 70.3% (PubMed=16778181).
CC   Sequence variation: Heteroplasmic for MT-ND1 p.Gly101Ter (m.3571insC); in 94.3% (PubMed=16778181).
CC   Sequence variation: Homozygous for PRKN p.Val380Leu (c.1138G>C); genomic (PubMed=26354775).
CC   Sequence variation: Homozygous for TP53 p.Pro151Thr (c.451C>A) (PubMed=31443247).
CC   Omics: Mitochondrial genome sequenced.
CC   Miscellaneous: STR profile from personal communication of Marlow L.A.
CC   Derived from metastatic site: Breast.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 12
ST   D18S51: 13,17
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 11
ST   D8S1179: 12
ST   FGA: 24.2
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C4946; Thyroid gland Hurthle cell carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 12-03-20; Version: 14
RX   PubMed=9669284; DOI=10.1089/thy.1998.8.475;
RA   Zielke A., Tezelman S., Jossart G.H., Wong M., Siperstein A.E.,
RA   Duh Q.-Y., Clark O.H.;
RT   "Establishment of a highly differentiated thyroid cancer cell line of
RT   Hurthle cell origin.";
RL   Thyroid 8:475-483(1998).
RX   PubMed=11349830; DOI=10.1089/10507250152039055;
RA   Savagner F., Chevrollier A., Loiseau D., Morgan C., Reynier P.,
RA   Clark O., Stepien G., Malthiery Y.;
RT   "Mitochondrial activity in XTC.UC1 cells derived from thyroid
RT   oncocytoma.";
RL   Thyroid 11:327-333(2001).
RX   PubMed=16646677; DOI=10.1089/thy.2006.16.325;
RA   Stankov K., Biondi A., D'Aurelio M., Gasparre G., Falasca A.,
RA   Romeo G., Lenaz G.;
RT   "Mitochondrial activities of a cell line derived from thyroid Hurthle
RT   cell tumors.";
RL   Thyroid 16:325-331(2006).
RX   PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171;
RA   Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A.,
RA   Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G.,
RA   Rugolo M., Romeo G.;
RT   "Defective oxidative phosphorylation in thyroid oncocytic carcinoma is
RT   associated with pathogenic mitochondrial DNA mutations affecting
RT   complexes I and III.";
RL   Cancer Res. 66:6087-6096(2006).
RX   PubMed=17725429; DOI=10.1089/thy.2007.0097;
RA   Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V.,
RA   Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R.,
RA   Trovisco V., Cirnes L., Alves C., Velho S., Soares P.,
RA   Sobrinho-Simoes M.;
RT   "Molecular and genotypic characterization of human thyroid follicular
RT   cell carcinoma-derived cell lines.";
RL   Thyroid 17:707-715(2007).
RX   PubMed=19087340; DOI=10.1186/1471-2407-8-371;
RA   Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.;
RT   "Conventional and molecular cytogenetics of human non-medullary
RT   thyroid carcinoma: characterization of eight cell line models and
RT   review of the literature on clinical samples.";
RL   BMC Cancer 8:371-371(2008).
RX   PubMed=26354775; DOI=10.1093/carcin/bgv122;
RA   Lee J., Ham S., Lee M.H., Kim S.J., Park J.H., Lee S.E., Chang J.Y.,
RA   Joung K.H., Kim T.Y., Kim J.M., Sul H.J., Kweon G.R., Jo Y.S.,
RA   Kim K.S., Shong Y.K., Gasparre G., Chung J.K., Porcelli A.M.,
RA   Shong M.;
RT   "Dysregulation of Parkin-mediated mitophagy in thyroid Hurthle cell
RT   tumors.";
RL   Carcinogenesis 36:1407-1418(2015).
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D.,
RA   Wezel T.V., Morreau H.;
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
RX   PubMed=31443247; DOI=10.3390/cancers11081185;
RA   Aydemirli M.D., Corver W., Beuk R., Roepman P.,
RA   Solleveld-Westerink N., van Wezel T., Kapiteijn E., Morreau H.;
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).